Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Net loss, excluding special items, was $0.04 per share in the November quarter, compared to a loss of $0.05 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 8% year-over-year to $72.8 million in the second quarter. The company continues to expect fiscal 2025 sales in the range of $282 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “We are very excited about our strong performance during the second quarter, and in particular the continued strength of our Med Tech segment,
which grew 25% over the prior year.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Can General Motors (GM) navigate the tariff challenge ahead?
General Motors' (NYSE: GM) stock tumbled last week after the Trump administration imposed new tariffs on automobile imports, raising concerns about their potential impact on the company’s production as it
What to look for when Delta Air Lines (DAL) reports its Q1 2025 earnings results
Shares of Delta Air Lines (NYSE: DAL) were down over 1% on Monday. The stock has dropped 28% over the past three months. The airline is scheduled to report its
STZ Earnings Preview: Can Constellation Brands leverage growing beer sales?
Constellation Brands, Inc. (NYSE: STZ) has effectively navigated challenges like cautious consumer spending and declining demand for its wine and spirits brands by capitalizing on the sustained growth in the
